FLGT
Fulgent Genetics Inc
21.60$
+1.3%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -9.1% | -0.4% | +0.2% | +0.1% | -1.1% | -1.2% | -0.5% | +1.2% | -0.1% | -4.7% | -5.8% | |
| – | -7.6% | -23.9% | +3.3% | -18.2% | +8.3% | +17.9% | +2.9% | +18.3% | +8.5% | -13.0% | -5.1% | |
| – | +15.9% | -43.9% | +19.1% | -10.9% | -5.0% | +22.0% | +30.6% | +33.9% | -57.3% | -53.4% | +12.4% | |
| – | -9.3% | -27.9% | +2.0% | -31.6% | +21.1% | +24.1% | -8.6% | +28.3% | -10.6% | -17.8% | -7.0% | |
| – | +5.2% | +3.4% | +7.3% | +1.9% | +18.7% | +4.4% | +5.7% | -7.4% | +16.4% | -17.3% | -6.9% | |
| – | +19.5% | +12.0% | +7.6% | +22.9% | -2.9% | +2.8% | +4.2% | +12.1% | +5.4% | +13.7% | -3.2% | |
| – | -84.5% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +13.7% | +0.0% | +114.2% | +0.2% | |
| – | -1.0% | -1.4% | -1.4% | -1.3% | -1.6% | -1.5% | -1.5% | +3.2% | -1.5% | +15.5% | -3.1% | |
| – | +5.7% | +1.2% | +0.1% | -4.4% | -8.2% | -8.6% | +6.3% | +6.4% | +13.9% | +5.1% | -16.9% | |
| – | +18.9% | +4.0% | -0.3% | -2.3% | -1.5% | -9.6% | +8.2% | +1.5% | +17.3% | +6.1% | -20.4% | |
| – | +77.9% | -35.4% | -18.7% | -29.9% | -2.0% | -2.6% | -7.9% | +18.0% | -1.3% | +24.6% | -3.2% | |
| – | -2.6% | +27.7% | +1.3% | -0.3% | -7.3% | -0.7% | +3.6% | -4.2% | +3.1% | +13.2% | -26.4% | |
| – | – | -15.9% | +0.0% | +0.0% | +0.0% | -21.5% | +0.0% | +0.0% | +0.0% | -24.6% | +0.0% | |
| – | -9.7% | -0.5% | +0.2% | +0.5% | -0.5% | -0.5% | -0.9% | +0.8% | -1.2% | -5.6% | -4.6% | |
| – | -16.8% | -2.1% | -1.4% | -2.4% | -1.0% | -2.0% | -3.3% | -1.2% | -4.2% | -4.7% | -5.8% | |
| – | -0.8% | 0.0% | +1.1% | +1.1% | +0.8% | +0.6% | +0.0% | -0.3% | +0.1% | +0.3% | -9.3% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.